Oncolytics Biotech (ONCY) Accumulated Expenses (2024 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Accumulated Expenses of $2.3 million for Q4 2025, down 9.6% year-over-year from $2.6 million in Q4 2024, and down 9.6% quarter-over-quarter from $2.6 million in Q4 2024.
Oncolytics Biotech (ONCY) Accumulated Expenses (2024 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Accumulated Expenses for 2 consecutive years, with $2.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses fell 9.6% year-over-year to $2.3 million; the TTM figure through Dec 2025 stood at $2.3 million (down 9.6% YoY), while the FY2025 annual figure was $2.3 million, down 9.6% from the prior year.
- Accumulated Expenses declined to $2.3 million in Q4 2025 per ONCY's latest filing, from $2.6 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $2.6 million in Q4 2024 and bottomed at $2.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.68 Mn |
| Dec 31, 2025 | 2.33 Mn |
| Dec 31, 2024 | 2.57 Mn |